Drugs / TSLPRCART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07572136 | Jul 2026 → Jun 2030 expected | B-cell acute lymphoblastic leukemia | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSLPRCART | “This will be the first in human testing of anti-CRLF2-R/TSLPR CAR T cell (TSLPRCART) adoptive cell therapy.” NCT07572136 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T cell therapy is a treatment that takes immune cells (T cells) from a person s body and modifies them to attack specific proteins.” NCT07572136 ↗ |
| Route | Intravenous | “then they will receive the modified cells through a tube inserted into a vein” NCT07572136 ↗ |
| Target | CRLF2 | “Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART)” NCT07572136 ↗ |